Where Does VKTX Stock Stand After the Obesity Pill Setback?

Viking Therapeutics (VKTX) recently experienced a setback following mixed mid-stage study results for its oral obesity drug, VK2735. While the drug achieved significant weight loss of 12.2% in patients, it also led to a high discontinuation rate of 28% due to adverse events, raising concerns about its tolerability and potential implications for the subcutaneous version now in late-stage development. This comes as VKTX trades at a premium valuation with widening loss per share estimates for 2025 and 2026, intensifying investor scrutiny within a rapidly expanding yet highly competitive obesity market dominated by Eli Lilly and Novo Nordisk.

Analysis

Viking Therapeutics (VKTX) faces significant clinical and financial headwinds following mixed mid-stage trial results for its oral obesity drug, VK2735. While the drug demonstrated efficacy, achieving up to 12.2% weight loss, this was undermined by a high patient discontinuation rate of 28% due to adverse events, raising material concerns about the drug's safety and tolerability profile. These concerns have created a negative overhang, potentially impacting the outlook for its late-stage subcutaneous (SC) formulation, for which data is not expected until late 2026 or early 2027. Financially, the company's position appears precarious; its stock trades at a premium price-to-book valuation of 3.66, above the industry average of 3.19, despite recent underperformance. This valuation is further challenged by deteriorating analyst sentiment, reflected in the widening of estimated losses per share for 2025 (to $2.48 from $1.87) and 2026 (to $3.15 from $2.54). The situation is compounded by intense competition from established market leaders Eli Lilly and Novo Nordisk, as well as Amgen, who are all advancing their own candidates in a market projected by Goldman Sachs to reach $100 billion by 2030.

Key Decisions for Investors

• Investors should scrutinize the high 28% dropout rate in the oral VK2735 study as a primary risk factor, as similar tolerability issues could jeopardize the more critical late-stage subcutaneous program.
• Given the stock's premium valuation (P/B of 3.66) juxtaposed with widening loss per share estimates for 2025 and 2026, it is prudent to reassess positions for potential valuation risk.
• Monitor competitive milestones from Eli Lilly, Novo Nordisk, and Amgen, as their progress in the obesity space could further diminish VKTX's market opportunity during its long clinical data-void period until late 2026.